ANN ARBOR, Mich., July 5 /PRNewswire/ -- Terumo Cardiovascular Systems Corporation (Terumo CVS) and Fresenius HemoCare GmbH announced today that they have signed a distributor and license agreement appointing Terumo CVS the exclusive distributor for the Fresenius C.A.T.S systems in the U.S. The agreement takes place one year after Terumo Medical Corporation acquired 3M's global cardiovascular business to form the subsidiary, Terumo CVS. Terumo CVS currently manufactures, markets, and sells CAPIOX, Sarns, and CDI brand products used in cardiac surgery to the U.S. and other global markets. The Fresenius C.A.T.S system is used primarily in cardiac surgery, as well as orthopedic surgery and trauma centers. The agreement will take effect August 1, 2000. Terumo Cardiovascular Systems is a subsidiary of Terumo Medical Corporation, the U.S. subsidiary of Terumo Corporation of Japan. Terumo Corporation is a premier global medical company with 1999 annual sales of approximately $1.6 billion. Terumo Corporation manufactures, markets and sells a wide range of medical products including syringes, needles, catheters, and blood bags. Terumo Cardiovascular Systems is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor, as well as Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. Fresenius HemoCare is a company of the Fresenius Health Care Group, which achieved world-wide sales in 1999 of approx. 5 billion Euros (+15%) with some 43,000 employees, and net income of 203 million Euros (+39%). Fresenius HemoCare provides a wide range of products and services for blood transfusion and cell separation, infusion of solutions and pharmaceuticals. The company also has expertise in cancer therapy and innovative adsorber processes for the treatment of blood outside the body.
SOURCE Terumo Cardiovascular Systems